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14 Abstract 
15 A number of veterinary clinical pathology laboratories in New Zealand have been reporting 
16 emergence of increased minimum in inhibitory concentrations for β-lactams in the common 
17 clinical bovine mastitis pathogen Streptococcus uberis. The objective of this study was to 
18 determine the genetic basis of this increase in MIC for β-lactam amongst S. uberis. Illumina 
19 sequencing and determination of oxacillin MIC was performed on 265 clinical isolates. 
20 Published sequences of the five penicillin binding proteins pbp1a, pbp1b, pbp2a, pbp2b, and 





























































22 Amino acid substitutions resulting from single nucleotide polymorphisms (SNP) within these 
23 genes were analysed for associations with elevated (≥ 0.5 mg/L) oxacillin MIC together with 
24 a genome wide association study. The population structure of the study isolates was 
25 approximated using a phylogenetic tree generated from an alignment of the core genome. A 
26 total of 53% of isolates had MIC ≥ 0.5 mg/L for oxacillin. A total of 101 substitutions within 
27 the five pbp were identified, of which 11 were statistically associated with an MIC ≥ 0.5 
28 mg/L. All 140 isolates which exhibited an increased β-lactam MIC had SNPs leading to 
29 pbp2x E381K and Q554E substitutions. The phylogenetic tree indicated that the genotype and 
30 phenotype associated with the increased MIC for oxacillin were present in several different 
31 lineages suggesting that acquisition of this increased β-lactam MIC had occurred in multiple 
32 geographically distinct regions. Reanalysis of the data from the intervention studies from 
33 which the isolates were originally drawn found a tendency for the pbp2x E381K substitution to 
34 be associated with lower cure rates. It is concluded that there is geographically and 
35 genetically widespread presence of pbp substitutions associated with reduced susceptibility to 
36 β-lactam antimicrobials. Additionally, presence of pbp substitutions tended to be associated 
37 with poorer cure rate outcomes following antimicrobial therapy for clinical mastitis. 
38 Key words: Streptococcus uberis; β-lactam resistance; penicillin binding proteins 
39 1. Introduction  
40 Streptococcus uberis is a common bovine mastitis pathogen (Bradley et al., 2007; 
41 McDougall et al., 2007b),. Its core genome consists of 1,530 genes and it is a highly 
42 recombinant species (Lang et al., 2009). Streptococcus uberis is highly heterogeneous as 
43 indicated by strain typing including random amplified polymorphic DNA (RAPD) 





























































45 (PFGE) (Zadoks et al., 2011). Isolates from the UK and New Zealand have been shown to 
46 have distinct MLST patterns, with a preponderance of ST-143 in New Zealand isolates, while 
47 ST-5 was predominant among the UK isolates (Pullinger et al., 2006). S. uberis may behave 
48 either as an environmental or contagious pathogen. Contagious transmission has been 
49 demonstrated through longitudinal studies and inferred from cross sectional studies in which 
50 the same sequence type is observed among cows or herds (Phuektes et al., 2001; Zadoks et 
51 al., 2003).  
52 Bacteriological cure rates following therapy of clinical S. uberis are reported to range 
53 between 64 and 91% (McDougall, 1998; McDougall et al., 2007a; Owens et al., 1997). Many 
54 factors influence the cure rate following mastitis therapy, including antimicrobial resistance 
55 (Sandholm et al., 1990). Because they do not produce β-lactamase (Zapun et al., 2008), 
56 Streptococci have historically been regarded as highly susceptible to β-lactams which are still 
57 the therapy of choice for infections with these bacteria. However, phenotypically β-lactam 
58 resistant bovine S. uberis isolates have been reported with bimodal distributions of minimum 
59 inhibitory concentrations (MIC) for cloxacillin in French, German and New Zealand studies 
60 (Guérin-Faublée et al., 2003; McDougall et al., 2014; Tenhagen et al., 2006).  
61 Penicillin-binding proteins (PBPs) are cell wall transpeptidases that catalyse assembly 
62 of cell wall peptidoglycan. Six pbp are found in S. pneumoniae: five high-molecular-mass 
63 pbp (pbp1a, pbp1b, pbp2x, pbp2a, and pbp2b) and one low-molecular-mass PBP (pbp3). 
64 pbp2a and 2b are essential, at least in S. pneumoniae, as double deletion results in non-
65 viability (Peters et al., 2016). The active site of transpeptidase activity is formed by three 
66 conserved amino acid motifs, SXXK, SXN, and KT(S)G. β-lactam resistance is generally 
67 associated with changes within, or flanking, these motifs. Mutations that confer resistance 





























































69 domains (Hakenbeck et al., 2012a). Low affinity variants of all the pbp have been described 
70 (Hakenbeck et al., 1999), but only mutations of pbp1a, -2x, and -2b appear to be associated 
71 with clinical β-lactam resistance (Grebe and Hakenbeck, 1996; Nagai et al., 2002). Low level 
72 resistance occurs with amino acid substitutions in pbp2b or 2x, while high level resistance 
73 requires additional amino acid substitutions in pbp1b or pbp3 (Du Plessis et al., 2002; Smith 
74 and Klugman, 1998). Alterations in the conserved motifs in pbp2b tend to be associated with 
75 resistance to penicillin, and alterations in pbp2x appear to contribute to low-level resistance to 
76 cephalosporins (Nagai et al., 2002). There is evidence of horizontal gene transfer amongst the 
77 streptococci, with a common resistance gene pool for S. pneumoniae, S. oralis and S. mitis 
78 (Dowson et al., 1994; Hakenbeck et al., 2012a). There is variation in the affinity of different 
79 β-lactams to pbp variants, which may reduce the clinical efficacy of different β-lactams in the 
80 face of emerging resistance (Garau, 2002; Grebe and Hakenbeck, 1996) in streptococci. It has 
81 been shown that resistant S. uberis isolates generated in the laboratory arise from alterations 
82 in pbp1a, pbp2b and/or pbp2x (Haenni et al., 2010b). β-lactam resistance mechanisms 
83 independent of substitutions amongst the pbp have been reported including the presence of  a 
84 murMN/fibAB operon, a mutation in the gene coding for GlcNAc deacetylase,  and  mutations 
85 in the gene mraY (Chewapreecha et al., 2014; Hakenbeck et al., 2012b). 
86 This study was undertaken to test the hypothesis that increases in MIC in clinical S. 
87 uberis isolates are associated with amino acid substitutions in one or more of the pbp.  
88 2. Materials and Methods 
89 Streptococcus uberis isolates collected during the conduct of two clinical mastitis 
90 antimicrobial therapy intervention studies were used for this study (Bryan et al., 2016; 





























































92 treatment from a total of 35 dairy farms in New Zealand (North Island and South Island) and 
93 were collected with permission of Animal Ethics Committees. 
94 Isolates that were Gram positive cocci, catalase negative, cleaved esculin, sorbitol and 
95 inulin and which did not grow in SF broth were initially defined as S. uberis. All isolates 
96 were subcultured onto an entire 5% blood agar plate containing 1% aesculin (Fort Richard, 
97 Auckland, New Zealand). From a pure culture, a single colony was picked and inoculated 
98 onto a Dorset egg slope (Fort Richard, Auckland, New Zealand), incubated overnight at 37°C 
99 and checked for growth before storage at 4 °C for further testing. The species of isolates was 
100 confirmed by MALDI-TOF (Pathology Associates LTD, Pathlab Bay of Plenty Division, 
101 Tauranga, New Zealand).  
102 2.1 Susceptibility testing 
103 The MIC of oxacillin was determined using a broth microdilution method according to 
104 CLSI standards (CLSI, 2013) using cation-adjusted Mueller-Hinton broth supplemented with 
105 2.5% lysed horse blood (CAMHB-LHB). Oxacillin solutions were prepared in CAMHB-LHB 
106 to a concentration range double of that the desired final concentrations of 0.0325 to 16 mg/L 
107 and dispensed into 96-well plates at 50 µl per well. Inoculum was prepared using colony 
108 suspension method to a turbidity equivalent to that of a 0.5 McFarland standard and was 
109 diluted 1:100 in CAMHB-LHB. For each test isolate, 50 µl of diluted isolate inoculum was 
110 added to the wells. Each isolate was tested in triplicate. The 96-well plates were then placed 
111 in a plastic bag to minimize evaporation and incubated at 35 °C for 20 h. Oxacillin was 
112 selected as we wished to determine the MIC for the penicillinase-stable penicillins including 
113 cloxacillin, which is commonly used for treatment of both clinical (Bryan et al., 2016, and 





























































115 to determine the epidemiological cut off (ECOFF) values by fitting a series of mixture 
116 models (Everitt, 1996) to the log-transformed MIC by maximum likelihood.  
117 Additional antibiotic susceptibility data was generated during the original clinical 
118 studies using either eTest (Biomerieux, France) or a custom-designed broth microdilution 
119 (Sensititre, Trek Diagnostics, Thermo Fisher, OH, USA) for penicillin, cefalexin, cefuroxime, 
120 ceftiofur, and cefquinome for subsets of the isolates. Streptococcus pneumoniae (ATCC 
121 49619) was run as a quality-control organism in parallel with the unknown isolates and the 
122 results were within the CLSI defined quality assurance standards.  
123 2.2 Molecular biology 
124 Genomic DNA was extracted from overnight cultures using the MasterPure Gram 
125 Positive DNA Purification Kit (Cambio, UK). Illumina library preparation was carried out as 
126 previously described (Quail et al., 2008), and sequencing performed on an Illumina HiSeq 
127 2000 following the manufacturer's standard protocols (Illumina, Inc, USA) at the Welcome 
128 Sanger Institute, Hinxton, UK (WSI).  
129 2.3 Bioinformatics  
130 Assemblies and annotations were generated using pipelines at the WSI (Page et al., 
131 2016). Assemblies were imported into Geneious (version 10.2.2, Geneious Inc, NZ) for 
132 analysis. The sequences for pbp1a, 1b, 2a, 2b and 2x were obtained from O140J S. uberis 
133 genome (NCBI accession number AM946015) and used to identify these genes in the study 
134 isolates. The pbp genes were extracted, aligned and single nucleotide polymorphisms (SNP) 
135 associated with amino acid substitution were identified. Amino acid sequences were aligned 
136 (and numbered) with those previously reported (Haenni et al., 2010b) for pbp1a, 2b and 2x, 
137 while amino acid numbering relative to the start of the open reading frame were used for 





























































139 For comparison with the sequence data from the study isolates, the sequences of 13 UK 
140 S. uberis (Hossain et al., 2015) were downloaded from European nucleotide archive 
141 (http://www.ebi.ac.uk/ena) and 63 Canadian S. uberis sequences were downloaded from 
142 PATRIC (www.patricbrc.org) (Vélez et al., 2017). 
143 Multilocus sequence types were determined from the genome sequenced data (Coffey et 
144 al., 2006) (http://pubmlst.org/suberis).  
145 A core genome alignment was obtained using Roary (Page et al., 2015) and a maximum 
146 likelihood phylogenetic tree was constructed using Randomized Accelerated Maximum 
147 Likelihood (RAxML)(Stamatakis, 2014). This tree was annotated using iTOL (Letunic and 
148 Bork, 2016). 
149 Initial associations between non-synonymous SNPs and the presence of an MIC above 
150 the ECOFF were examined using bivariate (χ2) statistics and binary logistic regression 
151 analyses. Subsequently forward and reverse multivariate logistic regression models were 
152 constructed to which all SNPS that were significant (P < 0.05) at the bivariate level were 
153 offered. This analysis was undertaken in STATA v10.2 (Stata Corp., College Station, TX, 
154 USA). Comparisons of MIC amongst other β-lactams for the specific SNPs were undertaken 
155 using Kruskal-Wallis non-parametric analyses, and regression analyses were used to compare 
156 the MIC of oxacillin with the MICs for other β-lactams.  
157 Subsequently a genome wide association study (GWAS) was undertaken using the 
158 oxacillin resistance MIC as the outcome using sequence element enrichment analysis (SEER; 
159 https://github.com/johnlees/seer) (Lees et al., 2016) and visualised using Phandango 
160 (Hadfield et al., 2017). K-mers (10-593bp) were generated from the isolate assemblies using 





























































162 (Ondov et al., 2016), which was projected onto a final distance matrix into 6 dimensions 
163 (selected on the basis of a Scree plot, data not shown) using R (script available at MRC 
164 Climb; climb.ac.uk) (Connor et al., 2016). SEER was then used to determine if any k-mers 
165 were associated with the cloxacillin resistance phenotype using a threshold adjusted for 
166 multiple testing of P < 5 x 10-8 (Barsh et al., 2012). 
167 Frequency of recombination events within the S. uberis genomes was estimated by 
168 performing a Genealogies Unbiased By recombinations In Nucleotide Sequences (Gubbins) 
169 analysis, (https://github.com/sanger-pathogens/Gubbins; Croucher et al 2015). A Roary 
170 alignment tree was used as the starting tree, the alignment was undertaken using SMALT, 
171 with O140J as the reference, and visualised using Phandango (Hadfield et al., 2017). 
172 2.4 Cure following intramammary therapy 
173 The association between the presence of the E381K substitution in pbp2x and cure rate 
174 (defined as absence of signs of clinical mastitis and/or non-isolation of the bacteria associated 
175 with clinical mastitis pre-treatment at 2 or 3 time points post treatment) following 
176 intramammary therapy was examined independently for the isolates from the two 
177 intervention studies. In the first study quarters with clinical mastitis were infused on three 
178 occasions at 24 hour intervals with either 1 g penicillin and 200 mg cloxacillin (PenClox 
179 1200 High Potency Milking Cow, Virbac, (NZ) Ltd, Hamilton, NZ), or with a combination of 
180 200 mg oxytetracycline, 100 mg oleandomycin, 100 mg neomycin and 5 mg prednisolone 
181 (Mastalone, Pfizer NZ Ltd., Auckland, NZ) (Bryan et al., 2016).  In the second intervention 
182 study affected quarters were treated by intramammary infusion at 12 hourly intervals with 
183 200 mg amoxycillin (as amoxycillin trihydrate), 50 mg clavulanic acid (as potassium 
184 clavulanate), and 10 mg prednisolone (Clavulox LC, Zoetis New Zealand Limited, Auckland, 





























































186 Generalised linear mixed models were used to assess the effect of treatment, E381K 
187 pbp2x genotype, and the treatment by genotype interaction on cure. For the first intervention 
188 study, herd was included as a random effect, and lactation number (i.e. categorised as first 
189 and second versus greater than second lactation) was also included as fixed effect.  For the 
190 second intervention study, the model also included days in milk at clinical mastitis diagnosis 
191 (categorised as ≤ 4 versus > 4 days), and age (categorised as 2, 3, 4-6, > 6-years-old). 
192 3. Results 
193 3.1 Distribution of minimum inhibitory concentrations and cut-off value 
194 The frequency distribution of MICs of oxacillin are shown in Fig. 1. The MIC50 and 
195 MIC90 were 1.0 and 2.0 mg/L. The ECOFF was defined as ≥ 0.5 mg/L based on visual 
196 assessment and the mixture modelling, and 141/265 (53.2%) of the isolates had an ECOFF 
197 greater or equal to this cutpoint.  
198 3.2 Penicillin binding proteins 
199 Penicillin binding proteins 1a, 1b, 2a, 2b and 2x were identified in all 265 isolates. The 
200 three conserved active site motifs were identified in pbp1a (S214TMK, S272SN, and K401TG), 
201 pbp1b (S441SIK, S497WN and K632TG), pbp2a (S454TIK, Y491GN and K632TG), PBP2b (S353VVK, 
202 S408SN, and K579TG), and in pbp2x (S339TMK, S398SN, and K549TG: Fig. 2). There was perfect 
203 alignment of the conserved active site motifs between the S. uberis pbp2x and S. pneumoniae 
204 (NCBI gene ID 934744). 
205 A total of 101 non-synonymous SNPs were identified across the 5 pbp. There were 19, 





























































207 3.3 Associations between SNPs and oxacillin resistance 
208 At a bivariate level, the 11 most common SNPs (i.e. present in ≥ 26 (10%) of the 
209 isolates) were associated with an oxacillin MIC greater or equal to the ECOFF within the 
210 transpeptidase domains of pbp1a, 2b and 2x, and pbp1b and 2a (Table 1).  
211 Of the 141 isolates having an oxacillin MIC greater or equal to the ECOFF, 140 of 
212 these had the pbp2x E381K, Q554E, and G600E substitutions. There was only one isolate without 
213 the E381K substitution that had an oxacillin MIC greater or equal to the ECOFF as it had an 
214 oxacillin MIC of 1 mg/L. A total of 133 of the isolates with an oxacillin MIC greater or equal 
215 to the ECOFF also had a pbp2x V590A substitution, and all of the V590A also had the E381K, 
216 Q554E, and G600E substitutions. There was no difference in the oxacillin MIC for isolates that 
217 did or did not have the V590A substitution within isolates with the E381K substitution (1.79 ± 
218 0.57 mg/L vs 1.66 ± 0.48 mg/L for isolates with and without the V590A substitution within the 
219 E381K substitution; P = 0.05).  
220 The E381K substitution was also associated with increases in MIC, relative to isolates 
221 without the substitution, for penicillin, cefuroxime,  ceftiofur, and cefquinome, but with a 
222 decrease in MIC for cefalexin (Table 2; Fig. 3). There was a positive association between 
223 oxacillin MIC and the MICs for penicillin (R2 = 0.58; P < 0.001), cefuroxime (R2 = 0.60; P < 
224 0.001), ceftiofur (R2 = 0.29; P < 0.001), ampicillin (R2 = 0.63; P < 0.001), cefquinome (R2 = 
225 0.43; P < 0.001) and ampicillin/clavulanic acid (R2 = 0.19; P < 0.001), but a negative 
226 association between oxacillin and cefalexin (R2 = 0.07; P < 0.001). 
227 There were 5 non-synonymous SNPs in the transpeptidase domain of pbp2x gene of the 
228 13 UK and 63 Canadian isolates (Table 1). All these variants, except the A492E substitution, 





























































230 Multivariable models for oxacillin resistance did not converge if any one of the E381K, 
231 Q554E, and G600E substitutions and any other SNPs were included.  
232 3.4 Multilocus sequence typing and Phylogenetic analysis 
233 A total of 146 sequence type were identified by MLST in the New Zealand isolates, a 
234 proportion of which had not previously been described (listed in Supplementary Table 1). 
235 While there was an association between MLST type and presence of the pbp2x E381K 
236 substitution  (P < 0.001), the E381K substitution was widely distributed throughout the 
237 phylogenetic tree and not found exclusively within one lineage (Supplementary Fig. 1).  
238 3.5 GWAS 
239 In the genome wide association study, the Manhattan plot (Supplementary Fig. 2) 
240 reveals a high level of association (peaking at P < 10-12) of k-mers within pbp2x and three 
241 other genes positioned next to this gene. Statistically significant candidate loci were detected 
242 in the pbp2x and mraY peptidoglycan biosynthesis pathway, and in two other genes yxeM and 
243 yxeN.  There were a total of 27, 42 and 11 SNPs in the mraY, yxeM, and yxeN genes, 
244 respectively of which 10, 18 and 4 were non-synonymous.  There were 3, 2, and 1 non-
245 synonymous SNPs with a prevalence of > 20% on mraY, yxeM, and yxeN genes, respectively, 
246 all of which were associated (P < 0.001) with the bpb2x E381K, Q554E, and G600E substitutions. 
247 No statistically significant SNPs were found in the cshB gene located between mraY and 
248 yxeM. 
249 3.6 Gubbins analysis 
250 A high level of genomic recombination was observed amongst the S. uberis genomes 





























































252 3.7 Cure rate 
253 In the first intervention study (Bryan et al., 2016), there was no significant effect of 
254 Treatment (P = 0.99), pbp2x E381K substitution (P = 0.13), or the treatment x pbp2x E381K 
255 substitution interaction (P = 0.41) on cure rate. However, the cure rate was numerically lower 
256 in quarters affected with S. uberis with the E381K substitution where treatment occurred with 
257 the β-lactam treatment (approximately 15% lower cure rate), while the cure rate of the E381K 
258 substitution was 4% lower following treatment with the non- β-lactam (Fig.  4a).  
259 In the second study (McDougall et al., 2019), presence of the E381K substitution tended 
260 (P = 0.07) to reduce bacteriological cure rate (Fig. 4b). While not significant (P = 0.11), 
261 numerically there appeared to be an interaction with the duration of treatment, whereby 
262 isolates with the E381K substitution treated for a longer duration (5 x 12 hourly) had higher 
263 bacteriological cure rates than isolates treated for a shorter period (3 x 12 hourly), whereas 
264 duration of treatment did not affect cure rate amongst the isolates without the substitution. 
265 4. Discussion 
266 A bimodal distribution of MICs for oxacillin was observed for S. uberis isolated from 
267 cases of bovine mastitis. A total of 53% of isolates had an MIC greater than the ECOFF of  ≥ 
268 0.5 mg/L. isolates with MICs  greater than the ECOFF were present on 28 of 30 farms 
269 located both in the North and South islands of New Zealand,  indicating wide geographic 
270 distribution and a low probability of direct cow to cow transmission of isolates with an MIC 
271 greater than the ECOFF.  
272 SNPs with possible association with the oxacillin MICs greater than the ECOFF were 
273 found on all 5 pbp (pbp1a, 1b, 2a, 2b and 2x). Following multivariable modelling, those on 





























































275 for oxacillin. This finding was confirmed by the results from a GWAS, which identified only 
276 pbp2x and 3 genes flanking this region. 
277 Substitutions in pbp1b and pbp2a have not been previously reported in S. uberis. 
278 However, substitutions in all pbp associated with phenotypic resistance have been reported to 
279 occur in S. pneumoniae (Hakenbeck et al., 2012a). The pbp1b G768S and the pbp2a T397A 
280 substitutions were also found in the Canadian and UK isolates, demonstrating wide 
281 geographic distribution of these substitutions. 
282 On pbp2b, 4 of the substitutions previously induced (Haenni et al., 2010b) were also 
283 observed in the current study in New Zealand, Canada and the UK; N366I, T402I, V570A and 
284 P575S. Three other substitutions were located in pbp2b in the New Zealand isolates, but none 
285 of these were associated with an increased MIC for oxacillin. As previously reported (Haenni 
286 et al., 2010b), the N366I substitution was located 13 residues downstream of the SVVK motif, 
287 the T402I SNP was located six residues before the SSN motif, and the V570A and P575S SNPs 
288 were located nine and four residues upstream of the KTG motif, respectively.  
289 For pbp2x, five substitutions associated with an increased MIC for oxacillin were 
290 located in the present study. All 5 were also located in the Canadian and UK isolates. The 
291 E381K and Q554E substitutions were previously reported as occurring in naturally occurring and 
292 induced resistant S. uberis (Haenni et al., 2010b), being 42 amino acids downstream of the 
293 STMK motif and five amino acids downstream of the KTG motif, respectively. All isolates 
294 with the pbp2x E381K, Q554E, and G600E substitutions had oxacillin MIC ≥ 0.5mg/L. Of the 
295 eight isolates with the pbp2x A590V substitution, seven of these also had the pbp2x E381K, 
296 Q554E, and G600E substitutions. This suggests that pbp2x E381K, Q554E, and G600E substitutions 





























































298 resistance for the one isolate without the E381K, Q554E, and G600E substitutions that had an 
299 elevated oxacillin MIC remains to be determined. 
300 The pbp2x Q554E substitution has been described in other penicillin resistant 
301 streptococci (Haenni et al., 2018). Restoring the wild type genotype at this position results in 
302 8 to 16 fold reduction in MIC (Dahesh et al., 2008), demonstrating the importance of this 
303 substitution. The pbp2x E381K substitution has not been described in Streptococci other than S. 
304 uberis (Haenni et al., 2010b; Hakenbeck et al., 2012a). The biological effect of the newly 
305 identified substitutions (I295V, V590A, G600E, G600D) are unclear. These substitutions were 
306 identified in all 3 populations of isolates examined. These substitutions were highly 
307 correlated with the E381K, Q554E, and G600E substitutions, hence in the current population the 
308 increased MIC for oxacillin could be entirely explained by the presence of the E381K and Q554E 
309 substitutions. The V590A, G600E, G600D substitutions are located in the α-helix of the 
310 transpeptidase domain. In S. pneumoniae, a N605T substitution is associated with decreased 
311 acetylation and reduced sensitivity to β-lactam antimicrobials (Carapito et al., 2006) and site-
312 directed mutagenesis has demonstrated that the reversion of the resistant Y595F substitution 
313 reduces the MIC (Smith and Klugman, 2005). Both of these substitutions are also within the 
314 α-helix of the transpeptidase domain (Hakenbeck et al., 2012a). Taken together these data 
315 suggest that the newly identified substitutions could contribute to reduced susceptibility of S. 
316 uberis to β-lactam antimicrobials. 
317 The E381K, Q554E, and G600E substitutions were also associated with increased MIC for 
318 other β-lactams including penicillin, ceftiofur, cefquinome, amoxicillin/clavulanic acid and 
319 cefuroxime. Only ceftiofur has a validated bovine mastitis clinical breakpoint (2 mg/L) and 
320 only 2 of 265 isolates in the current study had an MIC > 2 mg/L. For the other β-lactams, the 





























































322 cefuroxime, cephalexin and 2/1 mg/L for amoxicillin/clavulanic acid. In the absence of 
323 clinical breakpoints, while bimodal distributions for many of these antimicrobials were 
324 present, the clinical significance of this remains unclear. However, following intramammary 
325 infusion of 1 g of penicillin, which is a commonly used therapy in New Zealand, it is likely 
326 that concentrations greater than the maximum MIC for penicillin of the current isolates would 
327 be achieved. Following infusion of 1 million international units (i.e. approximately 606 mg) 
328 of penicillin G on 3 occasions at 12 hourly intervals, the mean milk concentration of 
329 penicillin was 175 mg/L (Moretain and Boisseau, 1989), approximately 700-fold higher than 
330 the MIC50 for penicillin found amongst the E381K substitute isolates in the current study. The 
331 E381K, Q554E, and G600E substitutions were associated with increased MIC for all β-lactams 
332 tested, other than cephalexin. Similarly, there was a positive association between the MIC for 
333 oxacillin and all other β-lactams, other than cefalexin. Different effects on sensitivity within 
334 antimicrobials class within mutations to pbp2x have been previously described. Laboratory 
335 pbp2x mutants which increased cefotaxime MIC by more than 10 fold had no effect, or 
336 increased, sensitivity to oxacillin (Grebe and Hakenbeck, 1996). 
337 4.1 Population structure 
338 The current study found multiple MLST types including many novel types. In common 
339 with a number of previous studies, it is clear that bovine mammary S. uberis are a highly 
340 diverse population (Davies et al., 2016; Zadoks et al., 2011).  There was limited evidence of 
341 clonal expansion within or between dairy herds in New Zealand, suggesting a predominantly 
342 environmental source of S. uberis in the New Zealand context, as distinct from cow to cow 
343 transmission inferred from some previous studies (Davies et al., 2016; Zadoks et al., 2011).  
344 Streptococci are generally found to be recombinogenic as seen in S. pneumoniae 





























































346 combination of point mutations, homologous recombination and movement of mobile genetic 
347 elements (Croucher et al., 2014).  This suggests that the association between the increased 
348 MIC for oxacillin and the pbp2x genotype is more likely to be causal and not just a result of 
349 clonal expansion of lineages carrying the pbp2x substitutions contained in a resistant 
350 background genome. The Gubbins analysis indicated that recombination events are 
351 particularly common in S. uberis. This places constraints on the interpretation of any 
352 phylogeny within this species not taking recombination into account although it should be 
353 noted that the maximum likelihood tree from the core genome shared much of the same 
354 structure as the tree from the Gubbins analysis (which accounted for recombination). As 
355 might be expected, the pbp2x E381K, Q554E, and G600E substitutions were conserved amongst 
356 closely related isolates using the core genome phylogeny. However, there were many 
357 examples of isolates within the same clade having different pbp2x genotypes suggesting 
358 multiple pbp2x mutation or acquisition events.  
359 4.2 GWAS 
360 The GWAS independently identified the pbp2x locus. Additionally, the mraY locus was 
361 identified which codes for phospho-N-acetylmuramoyl-pentapeptide-transferase, an enzyme 
362 responsible for the formation of the first lipid intermediate of the cell wall peptidoglycan 
363 synthesis. These two loci were also identified in a GWAS study of S. pneumoniae 
364 (Chewapreecha et al., 2014).  Two loci not previously reported as being associated with β-
365 lactam resistance in Streptococci were identified including yxeM which codes for an 
366 extracellular solute-binding protein and yxeN which codes for an ABC transporter permease. 
367 These later 2 genes flank pbp2x, and it is likely that they are associated due to linkage 
368 disequilibrium.  Interestingly cshB, which codes for a surface associated protein, and is 
369 located between mraY and yxeN, contained a number of SNPs, none of which were associated 





























































371 in the same location.  A number of loci identified in the GWAS of S. pneumoniae 
372 (Chewapreecha et al., 2014) including clpL, ciaH, ftsL and gpsB were not associated with β-
373 lactam resistance in the current study.   
374 4.3 Cure rate 
375 As the original intervention studies were not powered to specifically test the effect of 
376 E381K, Q554E, and G600E substitutions on bacteriological cure rate, care should be taken when 
377 interpreting the cure rate data given the relatively small sample size. 
378 However, numerically the cure rate was lower amongst S. uberis isolates with the E381K, 
379 Q554E, and G600E substitutions than those without these substitutions. The cure rate was 
380 numerically lower for isolates with E381K, Q554E, and G600E substitutions following treatment 
381 with a β-lactam compared with a non-β-lactam.  This is biologically plausible as the SNP in 
382 the pbp2x is only likely to affect β-lactams, and not the efficacy of antimicrobials operating 
383 via different mechanisms.  Increasing the duration of therapy with a β-lactam to 5 x 12 hourly 
384 tended to overcome the depression in cure rate seen with a shorter duration of therapy (i.e. the 
385 3 x 12 hourly treatment). Again, this is biologically plausible given that β-lactams are time-
386 dependent antimicrobials, hence with increasing duration it is feasible that concentrations 
387 above MIC were of sufficiently long duration to result in bacteriological cure even amongst 
388 isolates with increasing MIC.  Failure to detect difference in cure rate between pbp2x 
389 genotypes could also have been due to presence of other resistance mechanisms being present 
390 masking any effect of the pbp2x genotype. For example, in the first study the control group 
391 was treated with a combination of an aminoglycoside, a macrolide and a tetracycline. While 
392 streptococci are considered to constitutively resistant to aminoglycosides (Jayarao and Oliver, 
393 1992), there was no evidence of tetracycline resistance genes in the current study, and only 7 





























































395 data). Thus, it is considered unlikely that the failure to differentiate cure rate was due to a 
396 reduced cure rate in the non-β-lactam treatment group. 
397 The maximum MIC for cloxacillin of any isolates in the current study was 2 mg/L. 
398 Ongoing monitoring of the MIC of S. uberis isolates, and the association between MIC and 
399 clinical and bacteriological cure rates amongst clinical mastitis cases associated with S. 
400 uberis is required.  Additionally, as cloxacillin-based antimicrobials are the most commonly 
401 used at the end of lactation (i.e. for dry-cow therapy), it is plausible that ongoing use of 
402 antimicrobials at the end of lactation may result in selection of S. uberis with higher 
403 cloxacillin MIC. However, this hypothesis remains to be tested. 
404 5. Conclusions 
405 This study has found widespread evidence for increased MIC of oxacillin amongst the 
406 common bovine mastitis pathogen S. uberis. The great majority of isolates with an increased 
407 MIC for oxacillin were found to have substitutions in pbp2x, and the E381K, Q554E, and G600E 
408 substitutions were predictive of the increased MIC for oxacillin phenotype and did not 
409 require inclusion of substitutions on other pbp in the final predictive models. Isolates with the 
410 E381K, Q554E, and G600E substitutions were also found in Canadian, European and UK isolates, 
411 suggesting wide geographic distribution of this genotype. Phylogenetic analysis found the 
412 E381K, Q554E, and G600E substitutions were widely distributed amongst New Zealand clades, 
413 but there was variation in pbp2x genotype within closely related isolates. This suggests that 
414 horizontal gene transfer may be occurring, as has been reported in other Streptococci, or that 
415 multiple independent SNPs have occurred over time.  
416 Presence of the E381K, Q554E, and G600E substitutions was numerically associated with 





























































418 lactam intramammary therapy. Additionally, lower bacteriological cure rates occurred where 
419 this genotype was treated with a shorter compared with the longer duration of therapy. 
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602 Table 1  
603 Penicillin binding protein (PBP) number, residue number (based on previously reported 
604 (Haenni et al., 2010b) numbering for pbp1a, 2b and 2x, otherwise from the start of the open 
605 reading frame), most common residue at that position (core residue), the number of isolates 
606 with the core residue at that position, the amino acid of the variant and the number of isolates 
607 with this variant, the P-value from chi squared analysis of the variant against the isolate being 
608 resistant (that is, an oxacillin MIC of > 0.5 mg/L), and the number and percentage of isolates 
609 in core and variant amino acids with oxacillin resistance. Note only those substitutions with 
610 >10% prevalence and within the transpeptidase domain (for pbp1a, 2b and 2x) are listed. 
611 Where the same substitutions were identified in Canadian (Vélez et al., 2017) and UK 
612 (Hossain et al., 2015) isolates these are listed. 
613 Table 2  
614 The mean, standard error of the mean (SEM) and median minimum inhibitory concentration 
615 (MIC50; mg/mL) for β-lactam antimicrobials for Streptococcus uberis isolates with and 





























































617 Fig. 1. Frequency histogram of minimum inhibitory concentrations (mg/L) of oxacillin for 
618 Streptococcus uberis from bovine clinical mastitis cases. 
619 Fig. 2 a, b, c. Sites in (a) pbp1a, (b) pbp2b, and (c) pbp2x implicated in altered affinity to β-
620 lactams. The transpeptidase domain is represented as the horizontal black bar; the active site 
621 motifs are indicated in blue and marked by blue triangles. Numbers in brackets indicate the 
622 position of the first and last amino acids of the transpeptidase domain. The substitutions in 
623 green are from the current study, and the red substitutions are from those induced in S. uberis 
624 (Haenni et al., 2010a). Note only substitutions present in >10% of isolates in the current 
625 study are represented. 
626 Fig. 3. Box plots of the MIC of β-lactams for S. uberis isolates from bovine clinical mastitis 
627 cases defined as oxacillin resistant (i.e. MIC ≥ 0.5 mg/L) or susceptible (< 0.5 mg/L).  
628 Fig. 4 a,b. Estimated marginal mean (95% confidence intervals) for cure proportion for (a) 
629 study 1 for quarters infected with S. uberis that had the E381K substitution (open bar) or not 
630 (solid bar) by treatment type. The non-β-lactam treatment was daily intramammary infusion 
631 for 3 days of a combination of 200 mg oxytetracycline, 100 mg oleandomycin, 100 mg 
632 neomycin and 5 mg prednisolone, and β-lactam treatment was daily infusion 3 days of a 
633 combination of 1 g penicillin and 200 mg cloxacillin, and (b) cure proportion for quarters 
634 treated by intramammary infusion at 12 hourly intervals with 200 mg amoxycillin, 50 mg 





























































636 Supplementary Table 1.  Isolate identity, multilocus sequence type (Sequence type), 
637 oxacillin minimum inhibitory concentration (Ox MIC (mg/L)), resistance phenotype 
638 (resistant (1) =  ≥ 0.5 mg/L), resistance genotype (1 = pbp2x E381K substitution), location in 
639 New Zealand (North or South Island) and the unique farm identity (Farm_ID), ENA sample 





























































641 Supplementary Fig. 1. Phylogenetic tree of 265 S. uberis isolates from bovine clinical 
642 mastitis cases in New Zealand (classified as from the North or South Island) and S. uberis 
643 isolates from Canada and the UK. The tree is created from the core genome (~1,500 genes) of 
644 S. uberis. The meta data includes (from inner to outer) isolate number, multilocus sequence 
645 type, island of New Zealand, farm identity,  pbp2x E381K genotype (open green Square = wild 
646 (sensitive) genotype; closed green square = resistant genotype), and oxacillin MIC phenotype 
647 (red open square < 0.5 mg/L, closed red square ≥ 0.5 mg/L). 
648 Supplementary Fig. 2. Manhattan plot showing the results of a k-mer based genome wide 
649 association study using SEER visualised using Phandango. The reference genome used was 
650 17652_8#12.gff. The annotation file was generated by Prokka as part of the Welcome Sanger 
651 Institute Pathogen Informatics pipeline. The size of the dots indicates the length of positively 
652 associated k-mer. A threshold of P < 5x10-8 was applied. The vertical axis is the negative of 
653 the log10 value of P. The horizontal axis represents the base pair distance along the genome. 
654 Supplementary Fig. 3. Gubbins plot of 265 S. uberis isolates from bovine clinical mastitis 
655 cases in New Zealand. The phylogenetic tree (left panel) represents the maximum likelihood 
656 tree. The S. uberis 0140J genome is represented as the blue vertical bars across the top of the 
657 figure, while the vertical red bars in the centre of the figure represent the density estimates of 
658 recombination events. The line graph at the bottom of the figure is the cumulative frequency 
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Penicillin binding protein number (PBP), residue number (based on previously reported (Haenni et al., 2010b) numbering for pbp1a, 2b and 2x, otherwise 
from the start of the open reading frame), most common residue at that position (core residue), the number of isolates with the core residue at that position, 
the amino acid of the variant and the number of isolates with this variant, the P-value from chi squared analysis of the variant against the isolate being 
resistant (that is oxacillin MIC of >0.5 mg/L), and the number and percentage of isolates in core and variant amino acids with oxacillin resistance. Note only 
those substitutions with >10% prevalence and within the transpeptidase domain (for PBP1a, 2b and 2x) are listed. Where the same substitutions were 
identified in Canadian (Vélez et al., 2017) and UK (Hossain et al., 2015) isolates these are listed. 
New Zealand isolates Canadian isolates UK isolates
Core Resistant Variant Resistant Core Variant Variant Core Variant Variant
Gene Position AA no. no. % AA no. no. % P-value AA no. AA no. AA no. AA no. AA no. AA no.
pbp1a 452 S 175 73 41.7 N 90 68 75.6 0.000 N 50 S 13 N 11 S 2
Pbp1b 768 G 164 83 50.6 S 101 58 57.4 0.280 G 34 S 28 G 9 S 4
Pbp2a 44 E 179 107 59.8 G 86 34 39.5 0.002
Pbp2a 397 T 235 125 53.2 A 30 16 53.3 0.843 T 45 A 18 T 12 A 1
pbp2b 366 N 162 67 41.4 I 103 74 71.8 0.000 N 55 I 8 N 1 I 2
pbp2b 370 S 237 129 54.4 T 28 12 42.9 0.246
pbp2b 394 A 238 125 52.5 S 27 12 44.4 0.336
pbp2b 402 T 161 67 41.6 I 104 74 71.2 0.000 T 55 I 8 T 11 I 2
pbp2b 570 V 174 78 44.8 A 91 63 69.2 0.000 V 55 A 8 V 12 A 1
pbp2b 575 P 174 78 44.8 S 91 63 69.2 0.000 P 55 S 8 P 12 S 1
pbp2x 295 I 172 139 80.8 V 93 2 2.2 0.000 I 57 V 6 I 12 V 1
pbp2x 381 K 140 140 100.0 E 125 1 0.8 0.000 K 53 E 10 E 10 K 3
pbp2x 554 E 140 140 100.0 Q 125 1 0.8 0.000 E 52 Q 11 Q 11 E 2
pbp2x 590 A 133 133 100.0 V 132 8 6.1 0.000 A 45 V 18 V 11 A 2
pbp2x 600 E 140 140 100.0 G 125 1 0.8 0.000 E 49 G 11 D 3 G 10 E 2 D 1
E381K substitution No substitution
Mean SEM MIC50 Mean SEM MIC50 P-value
Penicillin 0.24 0.09 0.25 0.05 0.02 0.0625 0.05
Cefuroxime 0.63 0.27 0.5 0.06 0.11 0.025 0.05
Ceftiofur 1.52 1.47 1.0 0.15 0.13 0.025 0.05
Cefquinome 0.23 0.15 0.25 0.03 0.01 0.025 0.05
Cefalexin 0.34 0.22 0.25 0.51 0.29 0.5 0.05
